Detalles de la búsqueda
1.
IgA transcytosis and antigen recognition govern ovarian cancer immunity.
Nature;
591(7850): 464-470, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536615
2.
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Gynecol Oncol;
181: 54-59, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134754
3.
High Financial Hardship among Patients with Advanced Ovarian Cancer.
J Soc Work End Life Palliat Care;
: 1-13, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635421
4.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol;
178: 110-118, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37839313
5.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol;
170: 300-308, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758420
6.
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol;
173: 130-137, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148580
7.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol;
174: 213-223, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37229879
8.
"It doesn't really apply to what I'm going through": a mixed-methods study of barriers to palliative care among patients with advanced ovarian cancer.
Support Care Cancer;
31(7): 397, 2023 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37326676
9.
The impact of distance to closest negative margin on survival after pelvic exenteration.
Gynecol Oncol;
165(3): 514-521, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35487774
10.
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol;
167(3): 429-435, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36244828
11.
Trends in ureteral surgery on an academic gynecologic oncology service.
Gynecol Oncol;
163(3): 552-556, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34674890
12.
Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
Gynecol Oncol;
161(3): 693-699, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33812698
13.
"I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
Support Care Cancer;
29(5): 2663-2677, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32975643
14.
Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center.
Clin Genet;
97(2): 370-375, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31600840
15.
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol;
156(1): 23-31, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31791552
16.
High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
Gynecol Oncol;
156(2): 349-356, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31771865
17.
Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
Gynecol Oncol;
157(3): 706-710, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32143914
18.
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
Gynecol Oncol;
156(1): 131-139, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31759774
19.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Lancet Oncol;
20(6): 862-876, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31076365
20.
The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
Cancer;
125(4): 499-514, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570740